Glycotope GmbH
http://www.glycotope.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Glycotope GmbH
Deal Watch: GSK Makes $85m Wager On Surface’s Preclinical NK Cell Therapy
Although SRF813 isn’t likely to reach the clinic until 2021, GSK likes cell therapy’s monotherapy and combination potential. Lilly bids $880m to acquire neurodegenerative cell therapy firm Prevail.
Evotec Takes The Lead On EU-Backed Antibiotic R&D Project
The 11-member GNA NOW alliance aims to move a treatment for some of the most threatening drug-resistant bacteria through early-phase development by 2024 using a mix of public and private funds.
Deal Watch: Genentech Inks New Collaborations With Skyhawk, Convelo
Skyhawk continues its recent spate of deal-making, using its SkyStar platform in a deal with Genentech, which also is looking into neurology with Convelo. AbbVie buys STING specialist Mavupharma, while Recordati pays Novartis $390m for Cushing’s products.
New Antibiotic Class Is Aim Of Evotec R&D Pact With Nosopharm
Evotec and Nosopharm plan to develop and then test in humans the first novel antibiotic class for fighting Gram-negative Enterobacteriaceae infections in 40 years
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Glycotope Biotechnology
- Glycotope GmbH